2. Vías de señalización
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. Kinesin

Kinesin

Kinesin

Related Products

PDF 0.04 MB

Kinesins are a family of molecular motors that use the energy of ATP hydrolysis to move along the surface of, or destabilize, microtubule filaments. The kinesin motor protein family consists of 14 distinct subclasses and 45 kinesin proteins in humans. A large number of these proteins, or their orthologues, have been shown to possess essential function(s) in both the mitotic and the meiotic cell cycle. Kinesins also can be classified into three groups based on the position of their motor domains: N-terminal, C-terminal and internal kinesins. Conventional kinesin operates as a dimer, walking in a co-ordinated, hand-over-hand fashion along a microtubule protofilament.

Kinesins have important roles in chromosome separation, microtubule dynamics, spindle formation, cytokinesis and cell cycle progression. Roles of kinesins in diseases typically involve defective transport of cell components, transport of pathogens, or cell division.

Kinesin Isoform Specific Products:

Kinesin Isoform Comparison
Cat. No. Nombre del producto Efecto Pureza Chemical Structure
  • HY-145827
    KIF18A-IN-4
    		Inhibitor
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity.
    KIF18A-IN-4
  • HY-177285
    NVP-BQS481
    		Inhibitor
    NVP-BQS481 (Compound 1) is a selective Kinesin spindle protein-5 (Eg5) inhibitor with an IC50< 0.5 nM. NVP-BQS481 has significant antimitotic and antitumor activity (IC50: 0.0.9 nM for SK-OV-3ip cells). NVP-BQS481 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
    NVP-BQS481
  • HY-177613A
    ALN-12115 sodium
    		Inhibitor
    ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
    ALN-12115 sodium
  • HY-122130
    SCH 2047069
    		Inhibitor
    SCH 2047069 (MK-8267) is an orally active kinesin spindle protein (KSP) inhibitor (Kd: 0.5 nM) that can cross the blood-brain barrier. SCH 2047069 exhibits an IC50 value of ≤ 5 nM against the KSP ATPase. SCH 2047069 exhibits broad-spectrum antitumor activity. SCH 2047069 can induce mitotic arrest and apoptosis in tumor cells. SCH 2047069 can be used in the research of tumors such as ovarian cancer, colon cancer, glioblastoma, and lymphoma.
    SCH 2047069
  • HY-RS07257
    Kif12 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Kif12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kif12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Kif12 Mouse Pre-designed siRNA Set A
  • HY-158683
    KIF18A-IN-11
    		Inhibitor
    KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer.
    KIF18A-IN-11
  • HY-RS07255
    KIF11 Human Pre-designed siRNA Set A
    		Inhibitor

    KIF11 Human Pre-designed siRNA Set A contains three designed siRNAs for KIF11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    KIF11 Human Pre-designed siRNA Set A
  • HY-RS07258
    Kif12 Rat Pre-designed siRNA Set A
    		Inhibitor

    Kif12 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kif12 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Kif12 Rat Pre-designed siRNA Set A
  • HY-RS07256
    KIF12 Human Pre-designed siRNA Set A
    		Inhibitor

    KIF12 Human Pre-designed siRNA Set A contains three designed siRNAs for KIF12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    KIF12 Human Pre-designed siRNA Set A
  • HY-15187C
    Filanesib hydrochloride
    		Inhibitor 99.99%
    Filanesib (ARRY-520) hydrochloride is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity.
    Filanesib hydrochloride
  • HY-161112
    LG157
    		Inhibitor
    LG157 is a potent inhibitor of mitotic kinesin-like protein 2 (MKLP2).
    LG157
  • HY-181694
    SeSA-HCPT
    		Inhibitor
    SeSA-HCPT is an orally active dual-target inhibitor integrating Topo I and HDAC inhibition. SeSA-HCPT induces potent DNA damage, apoptosis, S-phase arrest in prostate cancer cells. SeSA-HCPT inhibits cancer cells proliferation and migration. SeSA-HCPT impairs homologous recombination by suppressing KIF4A-RAD51 signaling. SeSA-HCPT markedly inhibits CRPC tumor growth with minimal systemic toxicity.
    SeSA-HCPT
  • HY-162292
    Anticancer agent 190
    		Inhibitor
    Anticancer agent 190 (compound 3e) is an inhibitor targeting KSP (Kinesin) and PI3Kδ with activity against breast cancer.
    Anticancer agent 190
  • HY-162667
    EX05
    		Inhibitor
    EX05 is a potent KIF18A inhibitor with an IC50 value of 8.2 nM. EX05 has the potential for the research of cancer.
    EX05
  • HY-180641
    KIF18A-IN-19
    		Inhibitor
    KIF18A-IN-19 (Compound 1) is an orally active KIF18A inhibitor with an IC50 of <0.1 μM. KIF18A-IN-19 has anti-cancer activity against ovarian cancer.
    KIF18A-IN-19
  • HY-158757
    KIF18A-IN-12
    		Inhibitor
    KIF18A-IN-12 (compound 9) is a KIF18A inhibitor, with an IC50 value of 45.54 nM. KIF18A-IN-12 can be used in cancer research.
    KIF18A-IN-12
  • HY-164978
    KIF18A-IN-14
    		Inhibitor
    KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC50s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies.
    KIF18A-IN-14
  • HY-162110A
    (S)-AM-9022
    		Control 99.88%
    (S)-AM-9022 is the S-enantiomer of AM-9022 (HY-162110). AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer.
    (S)-AM-9022
  • HY-161897
    CENP-E-IN-2
    		Inhibitor
    CENP-E-IN-2 (compound 3) is a photoswitchable CENP-E inhibitor, with the pIC50 of 6.82 without light illumination and 5.85 with 365 nm light illumination. CENP-E-IN-2 has antitumor activity.
    CENP-E-IN-2
  • HY-162532
    KIF18A-IN-10
    		Inhibitor
    KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC50 value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells.
    KIF18A-IN-10
Cat. No. Nombre del producto / Synonyms Application Reactivity
Kinesin Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.